W.E. Berdel

Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)

K. Mross, P. Robben-Bathe, Lutz Edler et al. · Oncology Research and Treatment · 2000 · 54 citations

Serum Creatinine, Tumor Biology, Titanocene Dichloride +14

The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.

Carsten Bokemeyer, A. Harstrick, J. Beyer et al. · PubMed · 1998 · 47 citations

Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion

R. Thödtmann, Andreas Hüttmann, W.E. Berdel et al. · Investigational New Drugs · 1998 · 33 citations

Medicine, Intravenous Short Infusion, Clinical Pharmacology +5

A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma

Austin M. Seymour, Elisângela de Jesus Campos, Nicholas Thatcher et al. · European Journal of Cancer · 1995 · 17 citations

Hematological Malignancy, Solid Cancers, Medicine +12

cis-platinum (DDP) and VP 16-213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial

P.S. Mitrou, M. Graubner, W.E. Berdel et al. · European Journal of Cancer and Clinical Oncology · 1984 · 17 citations

Combination Chemotherapy, Medicine, Metronomic Therapy +7